{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:57:27Z","timestamp":1791280647770,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T00:00:00Z","timestamp":1132617600000},"content-version":"vor","delay-in-days":11224,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[1975,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>NZB\/NZW mice were treated with various immunosuppressive drugs used in human SLE. Cyclophosphamide (5 mg\/kg 6 days out of 7), alone or with prednisolone, was better than azathioprine, prednisolone, or azathioprine\u2010plus\u2010prednisolone, in prolonging survival and\/or reducing proteinuria, Coomb's antibodies, antinuclear antibodies, and glomerular deposits of \u03b3\u2010globulin. Intermittent bolus therapy with cyclophosphamide (50 mg\/kg\/10 days) was as effective as daily therapy. However, 61% of the mice receiving any cyclophosphamide regimen developed malignant tumors compared to none in the other groups.<\/jats:p>","DOI":"10.1002\/art.1780180212","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T16:28:06Z","timestamp":1171470486000},"page":"145-152","source":"Crossref","is-referenced-by-count":75,"title":["Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB\/NZW MICE"],"prefix":"10.1002","volume":"18","author":[{"given":"Bevra H.","family":"Hahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Knotts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom R.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,11,22]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"390","article-title":"Systemic lupus erythematosus in NZB X NZW mice treated with the corticosteroid drug betamethasone.","volume":"71","author":"Casey TP","year":"1968","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780150305"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780160205"},{"key":"e_1_2_1_5_2","first-page":"48","article-title":"Carcinogenic effect of azathioprine in young NZB\/B1 and NZB X NZW mice.","volume":"45","author":"Casey TP","year":"1967","journal-title":"Proc Univ Otago Med Sch"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V32.3.436.436","article-title":"Immunosuppression by cyclophosphamide in NZB X NZW mice with lupus nephritis.","volume":"32","author":"Casey TP","year":"1968","journal-title":"Blood"},{"key":"e_1_2_1_7_2","first-page":"199","article-title":"Cyclophosphamide treatment of mouse systemic lupus erythematosus.","volume":"21","author":"Horowitz RE","year":"1969","journal-title":"Lab Invest"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(66)91198-6"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(68)92778-5"},{"key":"e_1_2_1_10_2","first-page":"619","article-title":"Augmented incidence of neoplasia in NZB\/NZW mice treated with long term cyclophosphamide.","volume":"82","author":"Walker SE","year":"1973","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780150304"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780120403"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-76-3-365"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.127.3.507"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0019-2791(65)90004-2"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood.V25.4.423.423","article-title":"Autoimmune hemolytic anaemia in NZB\/B1 mice treated with the corticosteroid drug betamethasone.","volume":"25","author":"Casey TP","year":"1965","journal-title":"Blood"},{"key":"e_1_2_1_17_2","unstructured":"MorrisA TaylorJ LittletonC: Therapy and oncogenicity by different cyclophosphamide regimens in NZB\/NZW mouse nephritis. Presented at VI Pan American Congress on Rheumatic Diseases Toronto Ontario June1974(abstr)"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-76-4-619"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780180212","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780180212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T23:13:45Z","timestamp":1700694825000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780180212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1975,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1975,3]]}},"alternative-id":["10.1002\/art.1780180212"],"URL":"https:\/\/doi.org\/10.1002\/art.1780180212","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1975,3]]}}}